Clinical Trial Update: Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label trial assessing TLC399 for macular edema due to retinal vein occlusion; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion with Macular Edema
• Central Retinal Vein Occlusion with Macular Edema

Drugs mentioned

• TLC399

Snippet

Sponsor: Taiwan Liposome Company | Conditions: Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-12-23